|Videos|May 27, 2022
ASCO GU 2022 Updates: PARP Inhibitors in First-Line and Subsequent UC Settings
Experts comment on the utility of PARP inhibitors in UC and discuss data presented at ASCO GU 2022.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA granted priority review to perioperative durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive disease, based on phase 3 VOLGA data.
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
A positive CHMP opinion supports the perioperative use of pembrolizumab plus enfortumab vedotin in resectable MIBC regardless of cisplatin eligibility.
ASTRO’s first standalone clinical practice guideline for bladder cancer recommends trimodal therapy vs radical cystectomy for select muscle-invasive disease cases.
Advertisement
Advertisement
Trending on CancerNetwork
1
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
2
Acting on a HER2 Result and Navigating Access to Therapy
3
Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC
4
Subcutaneous Pembrolizumab Approved in Japan for All Tumor Indications
5